MedTrace Logo

A Study to Assess Efficacy and Safety of HL036 in Subjects With Dry Eyes

NCT03846453 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 637

Last updated 2022-04-14

Study results available
· View outcomes & findings →

Summary

The objective of this study was to compare the safety and efficacy of 0.25% HL036 Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.

Conditions

  • Dry Eye

Interventions

BIOLOGICAL

HL036 Ophthalmic Solution

HL036 Ophthalmic Solution

BIOLOGICAL

Placebo

Placebo vehicle solution

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    collaborator INDUSTRY

  • HanAll BioPharma Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-10
Primary Completion
2019-11-22
Completion
2019-11-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03846453 on ClinicalTrials.gov